In8bio INAB 深 滬
等待開盤 12-25 09:30:00 美东时间
2.00
+0.250
+14.29%
華盛通- 最 高2.00
- 今 開1.74
- 成交量 28.73万股
- 最 低 1.71
- 昨 收 1.75
- 總市值 907.94万
- 52周最高 12.531
- 市盈率 靜 --
- 換手率 6.33%
- 52周最低 1.17
- 委 比 -86.39%
- 總股本 453.97万
- 歷史最高 309.57
- 量 比 0.12
- 振 幅 16.57%
- 歷史最低 1.71
- 每 手 1
- 風險率 2.56%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Clene (NASDAQ:CLNN) stock increased by 10.0% to $7.94 during Wednesday'...
12-04 05:06
IN8bio Presents Consolidated INB-200 Phase 1 And INB-400 Phase 2 Glioblastoma Data At 2025 SNO Annual Meeting
IN8bio, Inc. (the "Company") presented consolidated data, a summary of which is located below, from its investigator-sponsored Phase 1 single-center clinical trial of INB-200 and its Company-sponsored Phase 2
11-25 03:53
IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site
IN8bio, Inc. announced the addition of The Ohio State University as a new clinical site in its Phase 1 trial for INB-100, a donor-derived allogeneic gamma-delta T cell therapy for patients with leukemias undergoing haploidentical stem cell transplantation. This expansion aims to accelerate enrollment and evaluate INB-100's safety, durability, and anti-leukemic activity post-transplant, with promising long-term remission data already observed.
10-29 12:00
IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications
INB-619 demonstrated equivalent efficacy to FDA-approved T Cell Engagers (TCE) for B cell depletion with minimal cytokine release, highlighting safer deep B cell depletion. It is the first pan-gamma delta T cell engager designed to expand multiple gamma delta T cell subsets for efficient target elimination. INB-619 achieved robust gamma delta T cell expansion and complete B cell depletion in both healthy donor and SLE samples. Unlike conventional...
10-27 12:00
IN8bio Q2 EPS $(1.24) Beats $(1.70) Estimate
IN8bio (NASDAQ:INAB) reported quarterly losses of $(1.24) per share which beat the analyst consensus estimate of $(1.70) by 27.06 percent. This is a 78.25 percent increase over losses of $(5.70) per share from the same
08-08 04:08
IN8bio Regains Nasdaq Compliance with Bid Price Rule
An update from IN8bio ( ($INAB) ) is now available. On June 24, 2025, IN8bio, I...
07-01 02:48
IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial
IN8bio announced that Patient 009 with grade 4 IDH-mutant glioma treated with INB-200 gamma-delta T cell therapy has achieved 4 years progression-free survival. This outcome surpasses typical results for IDH-mutant glioma patients and highlights the potential of gamma-delta T cell therapy for treating aggressive cancers. INB-200 demonstrated extended mPFS of 16.1 months in Phase 1 trial, exceeding the standard-of-care Stupp protocol's 6.9 months....
06-09 11:00
IN8Bio Announced New Long-term Clinical Data From Its Fully Enrolled Phase 1 Trial Of INB-200 In Patients With Newly Diagnosed Glioblastoma Multiforme, Demonstrating Prolonged Progression-Free Survival
Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp protocol.INB-200 is
06-02 19:32
